Finance

Beta
Lists
ABVX:EPA
Abivax SA
113,50 €
+0,98%
(+1,10) 1D
28-май, 17:35:26 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
115,00 €
High
117,50 €
Low
113,00 €
Mkt. cap
9,21 млд
Avg. vol.
127,11 миң
Volume
295,11 миң
52-wk high
132,00 €
52-wk low
5,12 €
EPS
-4,49 €
Shares outstanding
79,69 млн
No. of employees
69
Open
115,00 €
High
117,50 €
Low
113,00 €
Mkt. cap
9,21 млд
Avg. vol.
127,11 миң
Volume
295,11 миң
52-wk high
132,00 €
52-wk low
5,12 €
EPS
-4,49 €
Shares outstanding
79,69 млн
No. of employees
69
News stories
From sources across the web
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees69
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com
Last report
2026-ж., 22-май
Fiscal period
Q1 2026
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
1,34 млн / 343,06 миң
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
1,05 млн
639,00 миң
1,91 млн
1,34 млн
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
38,64 млн
55,42 млн
44,40 млн
49,54 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,94 млн
27,34 млн
27,69 млн
8,03 млн
Operating expense
47,54 млн
81,35 млн
73,56 млн
57,57 млн
Total operating expenses
47,54 млн
81,35 млн
73,56 млн
57,57 млн
Operating income
-46,50 млн
-80,71 млн
-71,65 млн
-56,23 млн
Other non operating income
2,66 млн
-74,20 млн
-4,96 млн
12,76 млн
EBT including unusual items
-48,41 млн
-153,36 млн
-76,11 млн
-48,24 млн
EBT excluding unusual items
-48,41 млн
-153,36 млн
-80,84 млн
-48,24 млн
Income tax expense
-
-
5,85 млн
228,00 миң
Effective tax rate
-
-
-7,68%
-0,47%
Other operating expenses
-46,00 миң
-1,40 млн
1,47 млн
-
Net income
-48,41 млн
-153,36 млн
-81,96 млн
-48,47 млн
Net profit margin
-4 624,07%
-23 999,69%
-4 282,13%
-3 606,25%
Earnings per share
-
-
-
-
Interest and investment income
190,00 миң
3,36 млн
1,19 млн
-
Interest expense
-3,52 млн
-4,21 млн
-15,27 млн
-4,77 млн
Net interest expenses
-3,33 млн
-852,00 миң
-14,08 млн
-4,77 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-46,47 млн
-80,63 млн
-70,76 млн
-55,86 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer